These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31893575)

  • 21. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.
    Tsuji S; Midorikawa Y; Takahashi T; Yagi K; Takayama T; Yoshida K; Sugiyama Y; Aburatani H
    Br J Cancer; 2012 Jan; 106(1):126-32. PubMed ID: 22095227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer.
    Ge L; Wang YF; Tian JH; Mao L; Zhang J; Zhang JH; Shen XP; Yang KH
    J Clin Pharm Ther; 2016 Aug; 41(4):383-91. PubMed ID: 27338003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
    Moreau LC; Rajan R; Thirlwell MP; Alcindor T
    Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer].
    Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1627-32. PubMed ID: 21996957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
    Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
    Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].
    de Gramont A; Tournigand C; Louvet C; André T; Molitor JL; Raymond E; Moreau S; Vignoud J; Le Bail N; Krulik M
    Rev Med Interne; 1997; 18(10):769-75. PubMed ID: 9500010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
    Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
    Strauss LG; Hoffend J; Koczan D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1226-34. PubMed ID: 19280186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
    Tong M; Zheng W; Lu X; Ao L; Li X; Guan Q; Cai H; Li M; Yan H; Guo Y; Chi P; Guo Z
    Oncotarget; 2015 Dec; 6(38):41216-27. PubMed ID: 26515599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cetuximab in association with an oxaliplatin-based chemotherapy as first-line treatment of metastatic colorectal cancer.].
    Petrelli F; Ghidini A; Zaniboni A
    Recenti Prog Med; 2017 Mar; 108(3):128-135. PubMed ID: 28398406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
    Yoshida Y; Hasegawa J; Nezu R; Kim YK; Hirota M; Kawano K; Izumi H; Kohno K
    Cancer Sci; 2011 Mar; 102(3):578-82. PubMed ID: 21205083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
    Huang MY; Huang ML; Chen MJ; Lu CY; Chen CF; Tsai PC; Chuang SC; Hou MF; Lin SR; Wang JY
    Pharmacogenet Genomics; 2011 Jan; 21(1):18-25. PubMed ID: 21057378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.